Tearsheet

DexCom (DXCM)

Market Price (4/11/2026): $64.0 | Market Cap: $24.7 Bil
Sector: Health Care | Industry: Health Care Equipment

DexCom (DXCM)

Market Price (4/11/2026): $64.0
Market Cap: $24.7 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 31%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 23%

Stock buyback support
Stock Buyback 3Y Total is 1.6 Bil

Low stock price volatility
Vol 12M is 43%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Diabetes Management, Wearable Health Devices, Show more.

Weak multi-year price returns
2Y Excs Rtn is -85%, 3Y Excs Rtn is -111%

Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 22x, P/EPrice/Earnings or Price/(Net Income) is 30x

Key risks
DXCM key risks include [1] heightened regulatory scrutiny, Show more.

0	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 31%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 23%
1	Stock buyback support Stock Buyback 3Y Total is 1.6 Bil
2	Low stock price volatility Vol 12M is 43%
3	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Diabetes Management, Wearable Health Devices, Show more.
4	Weak multi-year price returns 2Y Excs Rtn is -85%, 3Y Excs Rtn is -111%
5	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 22x, P/EPrice/Earnings or Price/(Net Income) is 30x
6	Key risks DXCM key risks include [1] heightened regulatory scrutiny, Show more.

Valuation, Metrics & Events

	4/11/26	2025	2024	2023	2022
Share Price CYE	$64.00	$68.29	$138.70	$116.18	$127.90
Market Cap CYE ($ Bil)	24.7	26.7	54.1	44.9	49.7
Total Debt ($ Bil)	1.4	2.6	2.6	2.1	2.1
Total Cash ($ Bil)	2.0	2.7	2.9	2.6	2.7
Enterprise Value ($ Bil)	24.1	29.3	56.7	47.0	51.8
Valuation Ratios
P/S TTM	5.3	6.4	14.2	14.9	19.3
P/EBIT TTM	22.4	35.6	67.8	102.6	182.8
P/E TTM	29.6	49.9	84.7	153.6	193.0
P/FCF TTM	23.0	46.4	92.8	108.0	525.8
Sector Ratios
P/S TTM (Sector)	3.8	3.3	4.1	4.3	6.0
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7	-1.3	-2.2
P/E TTM (Sector)	-1.8	-1.3	-2.0	-1.5	-2.2
P/FCF TTM (Sector)	-1.7	-1.2	-2.0	-1.5	-2.5

	4/11/26	2025	2024
Share Price CYE	$64.00	$68.29	$138.70
Market Cap CYE ($ Bil)	24.7	26.7	54.1
Total Debt ($ Bil)	1.4	2.6	2.6
Total Cash ($ Bil)	2.0	2.7	2.9
Enterprise Value ($ Bil)	24.1	29.3	56.7
Valuation Ratios
P/S TTM	5.3	6.4	14.2
P/EBIT TTM	22.4	35.6	67.8
P/E TTM	29.6	49.9	84.7
P/FCF TTM	23.0	46.4	92.8
Sector Ratios
P/S TTM (Sector)	3.8	3.3	4.1
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7
P/E TTM (Sector)	-1.8	-1.3	-2.0
P/FCF TTM (Sector)	-1.7	-1.2	-2.0

	DXCM	S&P 500
REVENUE GROWTH	GOOD
Rev LTM ($ Bil)	4.7
Rev Chg Q	13.1%	7.5%
Rev Chg LTM	15.6%	6.8%
Rev Chg 3Y Avg	17.1%	5.7%
PROFITABILITY	GOOD
Op Inc LTM ($ Bil)	0.9
CFO LTM ($ Bil)	1.4
Net Inc LTM ($ Bil)	0.8
Op Mgn LTM	19.6%	18.6%
CFO/Rev LTM	30.9%	20.6%
Net Inc Mgn	17.9%	12.8%
VALUATION	HIGH
P/S	5.3	3.2
P/CFO	17.2	15.4
P/FCF	23.0	19.8
P/E	29.6	24.1
STABILITY	VERY GOOD
Debt/Equity	0.06	0.21
Cash/Assets	0.32	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Total Global Customer Base	Approximately 2.8 – 2.9 million	12312024	Link
New Physicians in Prescriber Base	Over 50,000	12312024	Link
Stelo Users	Over 140,000	12312024	Link
Expanded Reimbursed Access (International)	More than 4 million people over the last 3 years	5082025	Link
Sensor and Other Recurring Revenue Percentage of Total Sales	97%	6302025	Link
Active Patents	1774	11052025	Link
Potential New Users from Expanded U.S. Commercial Coverage	More than 5 million	1142025	Link
New Customer Additions (2024)	Approximately 500,000 - 600,000 (excluding Stelo)	12312024	Link

Upcoming
4/30/2026	Earnings Release	Rev: $1.0 Bil (E) EPS: $0.47 (E)

Price Chart

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

DexCom (DXCM) stock has lost about 5% since 12/31/2025 because of the following key factors:

1. DexCom's Q4 2025 earnings beat expectations, but its 2026 revenue outlook slightly lagged analyst consensus, creating a mixed financial sentiment. The company reported Q4 2025 earnings per share (EPS) of $0.68, surpassing analysts' consensus estimates of $0.65. Quarterly revenue for Q4 2025 also rose 13.1% year-over-year to $1.26 billion, exceeding the consensus estimate of $1.25 billion. However, DexCom's initial revenue guidance for fiscal year 2026, projected to be between $5.16 billion and $5.25 billion (an 11-13% growth over 2025), fell slightly below the analyst consensus midpoint of $5.24 billion. This combination of strong past performance and a slightly conservative future outlook likely contributed to the stock remaining largely level as investors balanced these factors.

2. Persistent regulatory scrutiny and product reliability concerns, including past FDA Class I recalls and a recent software correction, weighed on investor confidence. In March 2025, the FDA reported that inspections revealed DexCom's G6 and G7 continuous glucose monitors were "adulterated" due to an unauthorized design change, leading to Class I recalls and a class-action lawsuit alleging inaccurate readings. Furthermore, in January 2026, the FDA issued a Class I software correction for certain Dexcom G6 and G6 Pro Android app versions, citing potential unexpected shutdowns that could halt glucose readings and alerts, posing risks of serious injury or death. These ongoing regulatory and quality issues likely tempered positive investor sentiment from financial performance or product advancements.

Show more

Stock Movement Drivers

Fundamental Drivers

The -3.5% change in DXCM stock from 12/31/2025 to 4/10/2026 was primarily driven by a -17.8% change in the company's P/E Multiple.

(LTM values as of)	12312025	4102026	Change
Stock Price ($)	66.37	64.02	-3.5%
Change Contribution By:
Total Revenues ($ Mil)	4,516	4,662	3.2%
Net Income Margin (%)	16.0%	17.9%	12.4%
P/E Multiple	36.0	29.6	-17.8%
Shares Outstanding (Mil)	391	387	1.2%
Cumulative Contribution			-3.5%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 4/10/2026

	Return	Correlation
DXCM	-3.5%
Market (SPY)	-5.4%	35.8%
Sector (XLV)	-4.8%	45.3%

Fundamental Drivers

The -4.9% change in DXCM stock from 9/30/2025 to 4/10/2026 was primarily driven by a -35.9% change in the company's P/E Multiple.

(LTM values as of)	9302025	4102026	Change
Stock Price ($)	67.29	64.02	-4.9%
Change Contribution By:
Total Revenues ($ Mil)	4,301	4,662	8.4%
Net Income Margin (%)	13.3%	17.9%	35.0%
P/E Multiple	46.2	29.6	-35.9%
Shares Outstanding (Mil)	392	387	1.4%
Cumulative Contribution			-4.9%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 4/10/2026

	Return	Correlation
DXCM	-4.9%
Market (SPY)	-2.9%	25.9%
Sector (XLV)	6.3%	33.8%

Fundamental Drivers

The -6.3% change in DXCM stock from 3/31/2025 to 4/10/2026 was primarily driven by a -36.1% change in the company's P/E Multiple.

(LTM values as of)	3312025	4102026	Change
Stock Price ($)	68.29	64.02	-6.3%
Change Contribution By:
Total Revenues ($ Mil)	4,033	4,662	15.6%
Net Income Margin (%)	14.3%	17.9%	25.6%
P/E Multiple	46.3	29.6	-36.1%
Shares Outstanding (Mil)	391	387	1.0%
Cumulative Contribution			-6.3%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2025 to 4/10/2026

	Return	Correlation
DXCM	-6.3%
Market (SPY)	16.3%	39.7%
Sector (XLV)	2.3%	34.5%

Fundamental Drivers

The -44.9% change in DXCM stock from 3/31/2023 to 4/10/2026 was primarily driven by a -77.5% change in the company's P/E Multiple.

(LTM values as of)	3312023	4102026	Change
Stock Price ($)	116.18	64.02	-44.9%
Change Contribution By:
Total Revenues ($ Mil)	2,910	4,662	60.2%
Net Income Margin (%)	11.7%	17.9%	53.0%
P/E Multiple	131.6	29.6	-77.5%
Shares Outstanding (Mil)	386	387	-0.1%
Cumulative Contribution			-44.9%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2023 to 4/10/2026

	Return	Correlation
DXCM	-44.9%
Market (SPY)	63.3%	27.2%
Sector (XLV)	19.1%	24.4%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
DXCM Return	45%	-16%	10%	-37%	-15%	-1%	-29%
Peers Return	58%	-33%	-19%	8%	-8%	-9%	-22%
S&P 500 Return	27%	-19%	24%	23%	16%	-0%	82%
Monthly Win Rates [3]
DXCM Win Rate	67%	42%	50%	33%	58%	75%
Peers Win Rate	53%	43%	42%	48%	45%	45%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
DXCM Max Drawdown	-12%	-49%	-33%	-48%	-29%	-7%
Peers Max Drawdown	-10%	-45%	-41%	-24%	-26%	-15%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-7%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: ABT, MDT, PODD, TNDM, SENS. See DXCM Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)

How Low Can It Go

Unique Key	Event	DXCM	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-58.2%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	139.5%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-36.8%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	58.2%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	29 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-48.0%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	92.3%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	193 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-87.0%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	666.9%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	488 days	1,480 days

Compare to ABT, MDT, PODD, TNDM, SENS

In The Past

DexCom's stock fell -58.2% during the 2022 Inflation Shock from a high on 11/17/2021. A -58.2% loss requires a 139.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About DexCom (DXCM)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

AI Analysis | Feedback

Here are 1-2 brief analogies for DexCom (DXCM):

Fitbit for blood sugar: Like how Fitbit continuously tracks activity and heart rate, DexCom continuously monitors glucose levels for people with diabetes.
Apple for diabetes management devices: DexCom provides sleek, user-friendly, and integrated continuous glucose monitoring systems that simplify a complex health condition, much like Apple simplifies technology.

AI Analysis | Feedback

DexCom G6: An integrated continuous glucose monitoring (CGM) system used for diabetes management.
Dexcom Real-Time API: An interface that enables third-party developers to integrate real-time CGM data into their digital health applications.
Dexcom ONE: A continuous glucose monitoring system designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Dexcom Share: A remote monitoring system that allows for sharing of continuous glucose monitoring data.
Dexcom G7: A next-generation continuous glucose monitoring (CGM) system that is part of the company's product candidature.

AI Analysis | Feedback

DexCom (symbol: DXCM) sells primarily to individuals, specifically people with diabetes, through prescriptions facilitated by healthcare providers. The company also states that its systems are "for use by healthcare providers." Based on the provided background information, the major categories of customers it serves are:

Individuals with Type 1 Diabetes: These patients often require continuous and precise glucose monitoring for intensive insulin management.
Individuals with Type 2 Diabetes: This includes patients who use insulin or require close glucose monitoring to manage their condition effectively.
Healthcare Providers: This category encompasses endocrinologists, physicians, and diabetes educators. While not always the direct purchasers, these professionals are crucial customers for DexCom as they prescribe the devices to patients and are the direct recipients of the company's marketing efforts. DexCom also provides its systems for use by these providers, implying direct engagement and support for their clinical practice.

AI Analysis | Feedback

null

AI Analysis | Feedback

Here is the management team for DexCom (DXCM):

Jacob Leach – President and Chief Executive Officer

Jacob "Jake" Leach is the President and Chief Executive Officer at Dexcom, a role he assumed effective January 1, 2026, succeeding Kevin R. Sayer. He joined Dexcom in 2004 and has over 20 years of experience in the continuous glucose monitoring industry. Prior to becoming CEO, he served as President and Chief Operating Officer, and before that, as Chief Technology Officer. Mr. Leach has been instrumental in supporting all major technology advancements at Dexcom, including the development of the first commercial Dexcom CGM system and all subsequent generations. He holds a Bachelor of Science degree in Electrical Engineering with a minor in Biomedical Engineering from the University of California, Los Angeles. He also serves on the Board of Directors at AdvaMed and is an Executive Committee member for the San Diego Economic Development Corporation.

Jereme Sylvain – Executive Vice President and Chief Financial Officer

Jereme Sylvain is the Executive Vice President and Chief Financial Officer at Dexcom, a position to which he was promoted in March 2021. In this role, he is responsible for Dexcom's finance organization and investor relations. Mr. Sylvain joined Dexcom in September 2018 as Vice President, Finance and Corporate Controller, and later served as Senior Vice President, Finance and Chief Accounting Officer. Before joining Dexcom, he held various positions at NuVasive, Inc., including Chief Accounting Officer and Vice President, Corporate Controller. His career also includes leadership roles at Thermo Fisher Scientific and experience with the public accounting firm Ernst & Young LLP. Mr. Sylvain received a Bachelor of Science degree in Finance from Arizona State University and a Master of Science in Accountancy from the University of Notre Dame, and is a Certified Public Accountant.

Michael Brown – Executive Vice President and Chief Legal Officer

Michael Brown serves as the Executive Vice President and Chief Legal Officer at Dexcom.

Jon Coleman – EVP, Chief Commercial Officer

Jon Coleman holds the position of Executive Vice President and Chief Commercial Officer at Dexcom.

Matthew Dolan – Executive Vice President, Strategy & Corporate Development & Dexcom Labs

Matthew Dolan is the Executive Vice President, Strategy & Corporate Development & Dexcom Labs at Dexcom.

AI Analysis | Feedback

Here are the key risks to DexCom's business:

Regulatory Scrutiny and Product Quality/Reliability Issues: DexCom faces significant risks related to regulatory compliance and the quality and reliability of its continuous glucose monitoring (CGM) systems. The U.S. FDA issued a warning letter to DexCom for unauthorized changes to a key sensor coating without submitting a premarket notification, which could increase risks for patients relying on CGMs for insulin dosing. Furthermore, FDA inspectors observed several quality control and process issues at DexCom's San Diego facility. There have been multiple recalls of DexCom G6 and G7 receivers due to defective foam or assembly errors that could lead to speaker malfunctions, preventing audible alerts for critical high or low blood glucose levels and potentially causing serious patient harm. DexCom's G7 system has also faced patient concerns regarding poor accuracy, failed sensor insertions, and abrupt stoppages. The company is currently facing class-action lawsuits alleging that it marketed defective G7 monitors, made unauthorized design changes, and that the devices provided inaccurate readings and failed to deliver critical alerts, leading to patient health risks and potentially severe consequences, including hospitalizations and alleged deaths.
Intensifying Competition: The continuous glucose monitoring market is experiencing increasing competition, posing a formidable threat to DexCom's market share and pricing power. Competitors like Abbott Laboratories, with its FreeStyle Libre solutions, are often cited as a significant rival, offering more competitively priced products and gaining market share. Medtronic is also a notable competitor. The integration of competitors' glucose-ketone dual analyte sensors and pump systems could further complicate DexCom's gains in the Type 1 diabetes segment.
Supply Chain and Manufacturing Challenges: DexCom relies on third-party suppliers and outsourced manufacturing, making its operations vulnerable to supply disruptions, quality issues, and price fluctuations. Manufacturing difficulties or disruptions at its facilities could adversely affect product sales and increase expenses. The company has experienced recent gross margin shortfalls and tempered margin forecasts due to supply issues, tariffs, foreign exchange headwinds, and increased scrap rates stemming from quality initiatives, highlighting vulnerabilities in its production and supply chain management.

AI Analysis | Feedback

null

AI Analysis | Feedback

Addressable Markets for DexCom's Main Products and Services

DexCom, Inc. primarily operates within the continuous glucose monitoring (CGM) systems market. The addressable markets for their main products, such as Dexcom G6, Dexcom G7, Dexcom ONE, and Dexcom Stelo, are encompassed by the broader CGM market.

Global Continuous Glucose Monitoring (CGM) Market

The global continuous glucose monitoring market was valued at approximately USD 10.9 billion in 2024. This market is projected to grow significantly, with estimates suggesting it will reach between USD 47.1 billion by 2034 and USD 55.048 billion by 2035, demonstrating a compound annual growth rate (CAGR) ranging from 15.7% to 16% during the forecast periods.

U.S. Continuous Glucose Monitoring (CGM) Market

The U.S. continuous glucose monitoring market was valued at approximately USD 4.9 billion in 2024. Projections indicate robust growth, with the market expected to reach USD 22 billion by 2034, exhibiting a CAGR of 16.2% from 2025 to 2034. Another estimate places the U.S. market at USD 7.43 billion in 2026, growing to USD 17.16 billion by 2031 with an 18.23% CAGR.

Dexcom Stelo Addressable Market (U.S.)

Dexcom's Stelo sensor, an over-the-counter CGM, targets approximately 25 million Americans with Type 2 diabetes who do not use insulin.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for DexCom (DXCM)

Over the next 2-3 years, DexCom (DXCM) is expected to drive future revenue growth through several key initiatives and market expansions:

Continued Adoption and Rollout of Dexcom G7: The successful launch and ongoing uptake of the Dexcom G7 and the newer G7 15 Day system are anticipated to be significant contributors to revenue growth. Management projects 2026 revenue growth, in part, due to the broad launch of the G7 15 Day system.
Expansion into the Type 2 Non-Insulin Market with Stelo: DexCom plans to significantly expand its addressable market by targeting people with Type 2 diabetes who do not use insulin through its new product, Stelo. This product was submitted to the FDA in Q4 2023 and is expected to launch in the U.S. in summer 2024, aiming to diversify revenue beyond high-acuity patients.
International Market Expansion and Increased Access: A consistent driver of growth is DexCom's strategy to broaden its global footprint. The company is actively expanding access and securing reimbursement in various international markets, including strong performance noted in France, Germany, the United Kingdom, Japan, and Canada.
Growth in Customer Base and CGM Awareness: The overall increase in awareness of continuous glucose monitoring (CGM) technology and the addition of new customers are fundamental drivers. DexCom has consistently demonstrated an ability to attract new users, reporting over 600,000 new DexCom users in 2023.
Expanded Reimbursement and Pharmacy Channel Penetration: DexCom is focused on expanding coverage for its CGM systems globally, particularly for Type 2 non-insulin users. This includes efforts to secure additional access through Medicare and partnerships with Pharmacy Benefit Managers (PBMs) to shift CGM device access toward pharmacy benefits, thereby increasing patient access and adherence.

AI Analysis | Feedback

Capital Allocation Decisions (2021-2025)

Share Repurchases

DexCom announced a share repurchase program of up to $500 million on October 27, 2023, which was valid until October 31, 2024.
On May 1, 2025, the company announced a new $750 million share repurchase program.
Annual share repurchases amounted to $688.7 million in 2023, $750 million in 2024, and $500 million in 2025.

Capital Expenditures

DexCom's capital expenditures for fiscal years ending December 2020 to 2024 averaged $309.7 million, with a median of $358.8 million.
Capital expenditures were $389 million in 2021, $365 million in 2022, $237 million in 2023, $359 million in 2024, and approximately $364 million for 2025.
Projected capital expenditures are set to increase, with $507 million anticipated for 2026, and further increases to $556 million in 2027 and $623 million in 2028. The primary focus of these expenditures includes investments in manufacturing, software, and organic growth, particularly to expand global manufacturing capacity.

Interactive Breakdown

null

null

Better Bets vs. DexCom (DXCM)

INDUSTRY: Health Care Equipment

Higher Rev Chg 3Y Avg | Lower P/S (Values for DXCM: 17.1% | 5.3x)

PODD (27.6% | 5.1x)

Insulet

GMED (43.5% | 4.1x)

Globus Medical

INSP (31.8% | 1.7x)

Inspire Medical Systems

UFPT (19.6% | 2.6x)

UFP Technologies

ATRC (17.4% | 2.5x)

AtriCure

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for DXCM: 17.1% | 27.1x)

GMED (43.5% | 22.6x)

Globus Medical

UFPT (19.6% | 16.7x)

UFP Technologies

PDEX (17.9% | 14.7x)

Pro-Dex

Higher Rev Chg LTM (Value for DXCM: 15.6%)

PODD (30.7%)

Insulet

ISRG (20.5%)

Intuitive Surgical

BSX (19.9%)

Boston Scientific

PEN (17.5%)

Penumbra

GMED (16.7%)

Globus Medical

Higher Rev Chg 3Y Avg (Value for DXCM: 17.1%)

GMED (43.5%)

Globus Medical

PODD (27.6%)

Insulet

GKOS (21.8%)

Glaukos

PEN (18.4%)

Penumbra

ISRG (17.4%)

Intuitive Surgical

Higher Op Mgn LTM (Value for DXCM: 19.6%)

IDXX (31.6%)

IDEXX Laboratories

ISRG (29.3%)

Intuitive Surgical

EW (27.0%)

Edwards Lifesciences

SYK (20.1%)

Stryker

BSX (19.8%)

Boston Scientific

Higher CFO/Rev LTM (Value for DXCM: 30.9%)

UTMD (38.1%)

Utah Medical Products

RMD (35.5%)

ResMed

LMAT (32.6%)

LeMaitre Vascular

TMDX (31.8%)

TransMedics

Higher FCF/Rev LTM (Value for DXCM: 23.1%)

UTMD (37.2%)

Utah Medical Products

RMD (32.9%)

ResMed

LMAT (29.8%)

LeMaitre Vascular

ISRG (24.7%)

Intuitive Surgical

IDXX (24.2%)

IDEXX Laboratories

Higher Total Yield (Value for DXCM: 3.4%)

MDT (7.4%)

Medtronic

MDLN (7.3%)

Medline

BDX (6.7%)

Becton Dickinson

ABT (6.1%)

Abbott Laboratories

SYK (3.5%)

Stryker

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for DXCM: 17.1% | 5.3x)

PODD (27.6% | 5.1x)

Insulet

NBIX (24.3% | 4.5x)

Neurocrine Biosciences

GMED (43.5% | 4.1x)

Globus Medical

ENSG (18.7% | 2.3x)

Ensign

BTSG (20.6% | 0.7x)

BrightSpring Health Services

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for DXCM: 17.1% | 27.1x)

UTHR (18.1% | 16.4x)

United Therapeutics

MEDP (20.3% | 26.1x)

Medpace

NBIX (24.3% | 20.3x)

Neurocrine Biosciences

GMED (43.5% | 22.6x)

Globus Medical

ENSG (18.7% | 26.9x)

Ensign

Higher Rev Chg LTM (Value for DXCM: 15.6%)

INSM (66.7%)

Insmed

ALNY (65.2%)

Alnylam Pharmaceuticals

LLY (44.7%)

Eli Lilly

ISRG (20.5%)

Intuitive Surgical

BSX (19.9%)

Boston Scientific

Higher Rev Chg 3Y Avg (Value for DXCM: 17.1%)

ALNY (54.8%)

Alnylam Pharmaceuticals

NTRA (41.5%)

Natera

INSM (36.8%)

Insmed

LLY (32.1%)

Eli Lilly

ISRG (17.4%)

Intuitive Surgical

Higher Op Mgn LTM (Value for DXCM: 19.6%)

LLY (45.6%)

Eli Lilly

MRK (34.0%)

Merck

ABBV (32.8%)

AbbVie

JNJ (27.2%)

Johnson & Johnson

AMGN (24.7%)

Amgen

Higher CFO/Rev LTM (Value for DXCM: 30.9%)

UTHR (49.1%)

United Therapeutics

RMD (35.5%)

ResMed

REGN (34.7%)

Regeneron Pharmaceuticals

GILD (34.0%)

Gilead Sciences

ABBV (31.1%)

AbbVie

Higher FCF/Rev LTM (Value for DXCM: 23.1%)

GILD (32.1%)

Gilead Sciences

ABBV (29.1%)

AbbVie

BMY (26.7%)

Bristol-Myers Squibb

VRTX (26.6%)

Vertex Pharmaceuticals

ISRG (24.7%)

Intuitive Surgical

Higher Total Yield (Value for DXCM: 3.4%)

MRK (8.8%)

Merck

UNH (7.2%)

UnitedHealth

JNJ (6.8%)

Johnson & Johnson

AMGN (6.8%)

Amgen

ABBV (4.3%)

AbbVie

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for DXCM: 17.1% | 5.3x)

BRK-B (27.0% | 2.5x)

Berkshire Hathaway

UBER (17.7% | 2.8x)

Uber Technologies

PGR (21.0% | 1.3x)

Progressive

MELI (38.9% | 3.1x)

MercadoLibre

PWR (18.7% | 3.1x)

Quanta Services

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for DXCM: 17.1% | 27.1x)

META (19.9% | 19.1x)

Meta Platforms

MU (45.3% | 16.8x)

Micron Technology

UBER (17.7% | 26.3x)

Uber Technologies

NEM (26.2% | 12.0x)

Newmont

AEM (28.1% | 17.4x)

Agnico Eagle Mines

Higher Rev Chg LTM (Value for DXCM: 15.6%)

MU (85.5%)

Micron Technology

NVDA (65.5%)

NVIDIA

AVGO (25.2%)

Broadcom

META (22.2%)

Meta Platforms

MSFT (16.7%)

Microsoft

Higher Rev Chg 3Y Avg (Value for DXCM: 17.1%)

NVDA (101.8%)

NVIDIA

MU (45.3%)

Micron Technology

BRK-B (27.0%)

Berkshire Hathaway

AVGO (26.2%)

Broadcom

META (19.9%)

Meta Platforms

Higher Op Mgn LTM (Value for DXCM: 19.6%)

NVDA (60.4%)

NVIDIA

MSFT (46.7%)

Microsoft

AVGO (41.5%)

Broadcom

AAPL (32.4%)

Apple

GOOGL (32.0%)

Alphabet

Higher CFO/Rev LTM (Value for DXCM: 30.9%)

MSFT (52.5%)

Microsoft

NVDA (47.6%)

NVIDIA

AVGO (43.5%)

Broadcom

GOOGL (40.9%)

Alphabet

AAPL (31.1%)

Apple

Higher FCF/Rev LTM (Value for DXCM: 23.1%)

V (55.4%)

Visa

NVDA (44.8%)

NVIDIA

AVGO (42.3%)

Broadcom

AAPL (28.3%)

Apple

MSFT (25.3%)

Microsoft

Higher Total Yield (Value for DXCM: 3.4%)

BRK-B (6.5%)

Berkshire Hathaway

MSFT (5.2%)

Microsoft

META (4.1%)

Meta Platforms

GOOGL (3.7%)

Alphabet

AAPL (3.5%)

Apple

Best Bets in Health Care

What You Pay

P/EBIT (Value for DXCM: 22.4x)

RPRX (12.6x)

Royalty Pharma

DOCS (16.5x)

Doximity

VEEV (27.0x)

Veeva Systems

HALO (16.5x)

Halozyme Therapeutics

UTHR (14.3x)

United Therapeutics

CPRX (11.9x)

Catalyst Pharmaceuticals

BMY (10.6x)

Bristol-Myers Squibb

RMD (18.1x)

ResMed

AMGN (16.1x)

Amgen

PBH (8.8x)

Prestige Consumer Healthcare

P/E (Value for DXCM: 29.6x)

RPRX (26.6x)

Royalty Pharma

DOCS (16.5x)

Doximity

VEEV (27.3x)

Veeva Systems

HALO (25.2x)

Halozyme Therapeutics

UTHR (18.6x)

United Therapeutics

CPRX (14.3x)

Catalyst Pharmaceuticals

BMY (16.9x)

Bristol-Myers Squibb

RMD (22.5x)

ResMed

AMGN (24.5x)

Amgen

PBH (14.5x)

Prestige Consumer Healthcare

What You Get

Rev Chg 3Y Avg (Value for DXCM: 17.1%)

RPRX (2.1%)

Royalty Pharma

DOCS (16.7%)

Doximity

VEEV (14.1%)

Veeva Systems

HALO (28.5%)

Halozyme Therapeutics

UTHR (18.1%)

United Therapeutics

CPRX (43.1%)

Catalyst Pharmaceuticals

BMY (1.5%)

Bristol-Myers Squibb

RMD (12.9%)

ResMed

AMGN (11.9%)

Amgen

PBH (-0.1%)

Prestige Consumer Healthcare

Rev Chg LTM (Value for DXCM: 15.6%)

RPRX (5.1%)

Royalty Pharma

DOCS (15.9%)

Doximity

VEEV (16.3%)

Veeva Systems

HALO (37.6%)

Halozyme Therapeutics

UTHR (10.6%)

United Therapeutics

CPRX (19.8%)

Catalyst Pharmaceuticals

BMY (-0.2%)

Bristol-Myers Squibb

RMD (9.6%)

ResMed

AMGN (10.0%)

Amgen

PBH (-1.3%)

Prestige Consumer Healthcare

Rev Chg Q (Value for DXCM: 13.1%)

RPRX (4.8%)

Royalty Pharma

DOCS (9.8%)

Doximity

VEEV (16.0%)

Veeva Systems

HALO (51.6%)

Halozyme Therapeutics

UTHR (7.4%)

United Therapeutics

CPRX (7.6%)

Catalyst Pharmaceuticals

BMY (1.3%)

Bristol-Myers Squibb

RMD (11.0%)

ResMed

AMGN (8.6%)

Amgen

PBH (-2.4%)

Prestige Consumer Healthcare

FCF/Rev 3Y Avg (Value for DXCM: 17.6%)

RPRX (118.0%)

Royalty Pharma

DOCS (41.6%)

Doximity

VEEV (40.8%)

Veeva Systems

HALO (38.8%)

Halozyme Therapeutics

UTHR (34.1%)

United Therapeutics

CPRX (33.2%)

Catalyst Pharmaceuticals

BMY (27.9%)

Bristol-Myers Squibb

RMD (27.3%)

ResMed

AMGN (26.4%)

Amgen

PBH (22.3%)

Prestige Consumer Healthcare

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	DexCom Earnings Notes	12/29/2026
2	DexCom Stock Surges 12%, With A 11-Day Winning Spree	12/12/2025
3	DexCom Stock 10-Day Winning Spree: Stock Climbs 9.5%	12/11/2025
4	8-Day Rally Sends DexCom Stock Up 6.4%	12/09/2025
5	Is 22.6% Fall In DexCom (DXCM) Stock A Buying Opportunity?	11/08/2025
6	ARTICLES
7	DXCM, BSX Look Smarter Buy Than IDEXX Laboratories Stock	04/10/2026
8	Pay Less, Gain More: DXCM, BSX Top IDEXX Laboratories Stock	03/24/2026
9	DXCM, BSX Top IDEXX Laboratories Stock on Price & Potential	03/11/2026
10	S&P 500 Movers \| Winners: COIN, AMAT, DXCM \| Losers: STZ, NCLH, NVR	02/14/2026
11	11-Day Rally Sends DexCom Stock Up 12%	12/12/2025

	Title
0	DASHBOARDS
1	DexCom Earnings Notes
2	DexCom Stock Surges 12%, With A 11-Day Winning Spree
3	DexCom Stock 10-Day Winning Spree: Stock Climbs 9.5%
4	8-Day Rally Sends DexCom Stock Up 6.4%
5	Is 22.6% Fall In DexCom (DXCM) Stock A Buying Opportunity?
6	ARTICLES
7	DXCM, BSX Look Smarter Buy Than IDEXX Laboratories Stock
8	Pay Less, Gain More: DXCM, BSX Top IDEXX Laboratories Stock
9	DXCM, BSX Top IDEXX Laboratories Stock on Price & Potential
10	S&P 500 Movers \| Winners: COIN, AMAT, DXCM \| Losers: STZ, NCLH, NVR
11	11-Day Rally Sends DexCom Stock Up 12%

Trade Ideas

Select ideas related to DXCM.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
PGNY_3312026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03312026	PGNY	Progyny	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	0.0%	0.0%	0.0%
CNC_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	CNC	Centene	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.3%	2.3%	-0.6%
OSCR_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	OSCR	Oscar Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.0%	3.0%	-2.6%
WAT_3202026_Monopoly_xInd_xCD_Getting_Cheaper	03202026	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-0.4%	-0.4%	-3.3%
GILD_3202026_Quality_Momentum_RoomToRun_10%	03202026	GILD	Gilead Sciences	Quality	Q \| Momentum \| UpsideQuality Stocks with Momentum and Upside Buying quality stocks with strong momentum but still having room to run	1.6%	1.6%	-2.2%
DXCM_10312025_Monopoly_xInd_xCD_Getting_Cheaper	10312025	DXCM	DexCom	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	7.9%	7.9%	-5.8%
DXCM_1312025_Monopoly_xInd_xCD_Getting_Cheaper	01312025	DXCM	DexCom	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-8.7%	-15.9%	-36.8%
DXCM_7312024_Dip_Buyer_High_CFO_Margins_ExInd_DE	07312024	DXCM	DexCom	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	27.4%	19.1%	-11.8%
DXCM_5312022_Dip_Buyer_High_CFO_Margins_ExInd_DE	05312022	DXCM	DexCom	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	48.2%	57.4%	-8.7%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
OGN	Organon	2.3	27.8%	23.5%
LWLG	Lightwave Logic	1.4	25.6%	227.2%
POET	POET Technologies	0.6	15.8%	11.2%
ALAB	Astera Labs	25.3	15.1%	-10.4%
MANE	Veradermics	1.4	14.7%	82.3%
TTMI	TTM Technologies	12.6	13.0%	76.1%
AAOI	Applied Optoelectronics	10.6	13.0%	332.0%
FBYD	Falcons Beyond Global	0.5	12.6%	-18.9%
TE	T1 Energy	0.8	12.2%	-29.8%
CRWV	CoreWeave	51.7	10.9%	42.4%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FSLY	Fastly	3.5	-21.7%	126.6%
REPL	Replimune	0.4	-19.5%	-51.0%
AKAM	Akamai Technologies	13.2	-16.7%	4.7%
FICO	Fair Isaac	21.9	-14.0%	-45.4%
SEZL	Sezzle	2.0	-13.6%	-5.9%
NET	Cloudflare	58.6	-13.5%	-15.3%
DOCN	DigitalOcean	6.9	-13.3%	57.1%
SMPL	Simply Good Foods	1.0	-11.5%	-48.0%
EVMN	Evommune	0.8	-11.0%	49.0%
GH	Guardant Health	10.1	-9.8%	-23.0%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
AEHR	Aehr Test Systems	2.1	58.9%	248.8%
CAR	Avis Budget	10.6	57.5%	133.7%
AAOI	Applied Optoelectronics	10.6	44.9%	332.0%
OGN	Organon	2.3	38.8%	23.5%
LWLG	Lightwave Logic	1.4	38.4%	227.2%
HUT	Hut 8	7.2	37.4%	43.9%
SLNO	Soleno Therapeutics	2.8	33.3%	13.7%
STAA	Staar Surgical	1.3	30.8%	14.5%
RIOT	Riot Platforms	5.8	29.1%	31.0%
CIFR	Cipher Digital	6.6	28.9%	12.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
REPL	Replimune	0.4	-43.4%	-51.0%
FSLY	Fastly	3.5	-31.1%	126.6%
SMPL	Simply Good Foods	1.0	-26.3%	-48.0%
AKAM	Akamai Technologies	13.2	-22.6%	4.7%
GWRE	Guidewire Software	10.0	-21.8%	-41.3%
OKTA	Okta	11.2	-21.5%	-27.2%
HUBS	HubSpot	10.1	-21.4%	-52.1%
NET	Cloudflare	58.6	-21.1%	-15.3%
VRDN	Viridian Therapeutics	1.4	-20.6%	-52.0%
SNOW	Snowflake	41.5	-20.2%	-44.8%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
XLO	Xilio Therapeutics	0.6	1475.9%	-5.1%
CAR	Avis Budget	10.6	196.4%	133.7%
SATL	Satellogic	1.0	135.7%	292.0%
LWLG	Lightwave Logic	1.4	111.2%	227.2%
APLS	Apellis Pharmaceuticals	5.2	110.5%	62.4%
FBYD	Falcons Beyond Global	0.5	92.1%	-18.9%
FLY	Firefly Aerospace	6.0	82.2%	67.8%
KOD	Kodiak Sciences	2.3	75.7%	54.2%
KODK	Eastman Kodak	1.2	74.0%	42.9%
ORKA	Oruka Therapeutics	3.2	73.1%	96.6%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
WVE	WAVE Life Sciences	1.3	-49.0%	-57.8%
VRDN	Viridian Therapeutics	1.4	-47.8%	-52.0%
MAZE	Maze Therapeutics	1.2	-47.1%	-35.6%
BUR	Burford Capital	1.0	-47.0%	-51.1%
FRMI	Fermi	2.9	-43.9%	-39.1%
TE	T1 Energy	0.8	-42.4%	-29.8%
REPL	Replimune	0.4	-39.7%	-51.0%
ADMA	ADMA Biologics	2.3	-38.1%	-46.8%
FIG	Figma	9.3	-34.8%	-51.4%
BOBS	Bobs Discount Furniture	1.4	-34.7%	-34.8%

Peer Comparisons

Peers to compare with:

Financials

	DXCM	ABT	MDT	PODD	TNDM	SENS	Median
Name	DexCom	Abbott L.	Medtronic	Insulet	Tandem D.	Senseoni.
Mkt Price	64.02	100.30	87.21	196.93	19.18	6.68	75.61
Mkt Cap	24.8	174.4	111.9	13.9	1.3	0.3	19.3
Rev LTM	4,662	44,328	35,483	2,708	1,015	35	3,685
Op Inc LTM	912	8,053	6,611	474	-167	-68	693
FCF LTM	1,077	7,395	5,410	350	-108	-60	714
FCF 3Y Avg	740	6,268	5,269	228	-77	-65	484
CFO LTM	1,441	9,566	7,285	569	-10	-59	1,005
CFO 3Y Avg	1,060	8,462	7,016	382	-6	-63	721

Growth & Margins

	DXCM	ABT	MDT	PODD	TNDM	SENS	Median
Name	DexCom	Abbott L.	Medtronic	Insulet	Tandem D.	Senseoni.
Rev Chg LTM	15.6%	5.7%	6.9%	30.7%	7.9%	56.9%	11.8%
Rev Chg 3Y Avg	17.1%	0.7%	4.9%	27.6%	9.0%	31.3%	13.1%
Rev Chg Q	13.1%	4.4%	8.7%	31.2%	2.7%	71.8%	10.9%
QoQ Delta Rev Chg LTM	3.2%	1.1%	2.1%	7.4%	0.8%	20.3%	2.7%
Op Mgn LTM	19.6%	18.2%	18.6%	17.5%	-16.5%	-193.8%	17.8%
Op Mgn 3Y Avg	17.0%	16.9%	18.5%	15.1%	-19.4%	-288.2%	16.0%
QoQ Delta Op Mgn LTM	2.3%	0.6%	-0.7%	0.2%	1.0%	16.7%	0.8%
CFO/Rev LTM	30.9%	21.6%	20.5%	21.0%	-1.0%	-167.7%	20.8%
CFO/Rev 3Y Avg	25.4%	20.0%	20.8%	16.8%	-0.9%	-250.0%	18.4%
FCF/Rev LTM	23.1%	16.7%	15.2%	12.9%	-10.7%	-170.9%	14.1%
FCF/Rev 3Y Avg	17.6%	14.8%	15.7%	9.8%	-9.1%	-255.2%	12.3%

Valuation

	DXCM	ABT	MDT	PODD	TNDM	SENS	Median
Name	DexCom	Abbott L.	Medtronic	Insulet	Tandem D.	Senseoni.
Mkt Cap	24.8	174.4	111.9	13.9	1.3	0.3	19.3
P/S	5.3	3.9	3.2	5.1	1.3	8.6	4.5
P/EBIT	22.4	19.5	17.8	34.7	-6.7	-4.7	18.6
P/E	29.6	26.7	24.2	56.1	-6.4	-4.4	25.5
P/CFO	17.2	18.2	15.4	24.3	-134.2	-5.1	16.3
Total Yield	3.4%	6.1%	7.4%	1.8%	-15.7%	-22.9%	2.6%
Dividend Yield	0.0%	2.4%	3.2%	0.0%	0.0%	0.0%	0.0%
FCF Yield 3Y Avg	2.4%	3.1%	4.7%	1.2%	-4.6%	-20.8%	1.8%
D/E	0.1	0.1	0.3	0.1	0.3	0.1	0.1
Net D/E	-0.0	0.0	0.2	0.0	0.1	-0.2	0.0

Returns

	DXCM	ABT	MDT	PODD	TNDM	SENS	Median
Name	DexCom	Abbott L.	Medtronic	Insulet	Tandem D.	Senseoni.
1M Rtn	-3.5%	-9.0%	-1.2%	-17.5%	-13.4%	14.4%	-6.2%
3M Rtn	-5.0%	-19.9%	-9.9%	-31.9%	-11.6%	-7.5%	-10.7%
6M Rtn	-1.7%	-23.6%	-7.2%	-37.4%	37.0%	-20.5%	-13.8%
12M Rtn	-4.9%	-17.9%	9.0%	-21.7%	12.6%	-41.5%	-11.4%
3Y Rtn	-44.3%	3.0%	18.7%	-37.3%	-54.8%	-44.3%	-40.8%
1M Excs Rtn	-4.1%	-9.6%	-1.8%	-18.1%	-14.1%	13.8%	-6.8%
3M Excs Rtn	-4.9%	-18.6%	-9.4%	-31.3%	-13.2%	-4.7%	-11.3%
6M Excs Rtn	-6.5%	-25.5%	-10.4%	-38.5%	24.1%	-28.6%	-18.0%
12M Excs Rtn	-31.3%	-54.4%	-26.9%	-57.1%	-19.6%	-72.8%	-42.8%
3Y Excs Rtn	-110.9%	-62.8%	-45.3%	-104.7%	-119.2%	-110.1%	-107.4%

Comparison Analyses

	Title
0	How Does DexCom Stock Stack Up Against Its Peers?
1	DXCM Could Deliver 46% Returns And Outperform MDT
2	DexCom vs. Boston Scientific: With Return Forecast Of 86%, DexCom Is A Better Bet
3	DXCM or PODD - With 73% Return Forecast, PODD Probably Deserves Your Money
4	DexCom vs. Abbott Laboratories: With Return Forecast Of 85%, DexCom Is A Better Bet
5	DexCom vs. Illumina: With Return Forecast Of 86%, DexCom Is A Better Bet
6	DexCom vs. Twitter: With Return Forecast Of 93%, DexCom Is A Better Bet
7	DexCom vs. Intuitive Surgical: With Return Forecast Of 93%, DexCom Is A Better Bet
8	DexCom vs. Salesforce: With Return Forecast Of 206%, Salesforce Is A Better Bet
9	DexCom vs. Twilio: With Return Forecast Of 93%, DexCom Is A Better Bet

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021	2020
Period End	12/31/2025	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	2/12/2026	2/12/2026	2/18/2025	2/8/2024	2/9/2023	2/14/2022	2/11/2021
Key Financials
Total Revenue	4,662	4,662	4,033	3,622	2,910	2,448	1,927
EBITDA	1,358	1,358	946	917	565	378	377
Operating Income	912	912	600	598	391	266	300
Net Income	836	836	576	542	341	217	494
EPS	2.15	2.14	1.46	1.40	0.88	0.56	1.31
Growth Rates
Total Revenue Growth	15.6%	15.6%	11.3%	24.5%	18.8%	27.1%	30.5%
EBITDA Growth	43.7%	43.7%	3.2%	62.2%	49.7%	0.2%	76.7%
Operating Income Growth	52.0%	52.0%	0.4%	52.8%	47.2%	-11.3%	110.5%
Net Income Growth	45.1%	45.1%	6.4%	58.7%	57.3%	-56.1%	388.2%
Margins
EBITDA Margin	29.1%	29.1%	23.4%	25.3%	19.4%	15.4%	19.6%
Operating Income Margin	19.6%	19.6%	14.9%	16.5%	13.4%	10.9%	15.5%
Net Income Margin	17.9%	17.9%	14.3%	14.9%	11.7%	8.9%	25.6%
Cash & Debt
Total Cash	1,999	1,999	2,579	2,724	2,456	2,731	2,708
Total Debt	1,390	1,390	2,587	2,594	2,145	2,158	1,840
Net Debt / (Cash)	-609	-609	8	-130	-311	-573	-868
Cash Flows
Net Cash from Operations	1,441	1,441	990	748	670	442	476
Free Cash from Operations	1,077	1,077	631	512	305	53	277
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	313	500	750	689	558	-0	-0

$ Mil \| FY: 12/31	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Period End	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023
Filing Date	2/12/2026	10/30/2025	7/30/2025	5/1/2025	2/18/2025	10/24/2024	7/25/2024	4/25/2024	2/8/2024	10/26/2023	7/27/2023	4/27/2023
Key Financials Quarterly
Total Revenue	1,260	1,209	1,157	1,036	1,114	994	1,004	921	1,034	975	871	742
Ebitda	410	421	309	219	274	237	245	190	304	294	209	111
Operating Income	323	242	213	134	189	152	158	101	217	206	128	47
Net Income	267	284	180	105	152	135	144	146	256	121	116	49
EPS	0.69	0.73	0.46	0.27	0.39	0.34	0.36	0.38	0.67	0.31	0.30	0.13
Key Financials TTM
Total Revenue TTM	4,662	4,516	4,301	4,148	4,033	3,954	3,935	3,802	3,622	3,403	3,198	3,022
Ebitda TTM	1,358	1,222	1,039	975	946	975	1,031	996	917	787	684	598
Operating Income TTM	912	778	687	633	600	628	682	652	598	506	448	397
Net Income TTM	836	721	572	535	576	681	667	639	542	377	358	292
Growth Rates Quarterly
Total Revenue Growth	13.1%	21.6%	15.2%	12.5%	7.6%	2.0%	15.3%	24.2%	26.9%	26.7%	25.2%	17.9%
EBITDA Growth	49.7%	77.2%	26.2%	15.5%	-9.7%	-19.1%	17.1%	71.3%	74.3%	54.5%	69.0%	41.4%
Operating Income Growth	71.0%	59.5%	34.6%	32.2%	-12.9%	-26.0%	23.3%	114.2%	73.0%	39.3%	66.4%	14.3%
Net Income Growth	76.2%	110.8%	25.3%	-28.0%	-40.8%	11.5%	23.8%	201.2%	179.2%	19.3%	127.7%	-50.1%
Margins Quarterly
EBITDA Margin	32.6%	34.8%	26.7%	21.1%	24.6%	23.9%	24.4%	20.6%	29.3%	30.1%	24.0%	14.9%
Operating Income Margin	25.6%	20.1%	18.4%	12.9%	17.0%	15.3%	15.7%	11.0%	21.0%	21.1%	14.7%	6.4%
Net Income Margin	21.2%	23.5%	15.5%	10.2%	13.6%	13.5%	14.3%	15.9%	24.8%	12.4%	13.3%	6.6%
Cash & Debt
Total Cash	1,999	3,322	2,929	2,701	2,579	2,492	3,121	2,897	2,724	3,240	3,636	2,567
Total Debt	1,390	2,576	2,579	2,583	2,587	2,591	2,594	2,590	2,594	2,719	3,372	2,143
Net Debt / (Cash)	-609	-746	-350	-118	8	99	-526	-307	-130	-521	-265	-424
Cash Flows Quarterly
FCF from Operations	294	660	303	184	301	200	279	209	134	269	190	155
Cash Flows TTM
FCF from Operations TTM	1,441	1,448	988	964	990	822	891	802	748	747	771	754
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	313	-0	-0	-0	-0	750	-0	-0	500	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-	-	-	-	6780.9%	466.4%	-	-	-	-	91.5%	20.8%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-	-	-	-	6095.2%	581.1%	-	-	-	-	78.2%	40.4%

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022	2021
Single Segment	3,622	2,910	2,448	1,927	1,476
Total	3,622	2,910	2,448	1,927	1,476

Operating Income by Segment

$ Mil	2025	2024	2023	2022	2021
Single Segment	598
Total	598

Net Income by Segment

$ Mil	2025	2024	2023	2022	2021
Single Segment	542
Total	542

Price Behavior

Price Behavior

Market Price	$64.02
Market Cap ($ Bil)	24.8
First Trading Date	04/14/2005
Distance from 52W High	-28.5%
	50 Days	200 Days
DMA Price	$68.49	$71.22
DMA Trend	down	down
Distance from DMA	-6.5%	-10.1%
	3M	1YR
Volatility	33.8%	41.7%
Downside Capture	0.77	0.67
Upside Capture	187.55	86.84
Correlation (SPY)	30.3%	26.6%

DXCM Betas & Captures as of 3/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	0.75	0.94	0.89	0.77	0.91	0.84
Up Beta	-0.09	-1.59	-0.96	0.36	0.97	0.83
Down Beta	-0.05	0.43	0.14	0.68	0.74	0.75
Up Capture	104%	164%	198%	90%	81%	36%
Bmk +ve Days	7	16	27	65	139	424
Stock +ve Days	8	17	29	70	129	381
Down Capture	140%	150%	135%	89%	105%	102%
Bmk -ve Days	12	23	33	58	110	323
Stock -ve Days	14	25	34	56	118	364

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with DXCM
DXCM	6.3%	42.8%	0.26	-
Sector ETF (XLV)	12.3%	16.8%	0.52	33.7%
Equity (SPY)	31.2%	17.3%	1.47	35.5%
Gold (GLD)	60.1%	27.8%	1.69	5.4%
Commodities (DBC)	29.8%	16.6%	1.58	7.5%
Real Estate (VNQ)	21.3%	15.2%	1.07	28.0%
Bitcoin (BTCUSD)	-5.7%	43.7%	-0.01	17.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with DXCM
DXCM	-6.9%	46.8%	0.02	-
Sector ETF (XLV)	6.3%	14.6%	0.25	37.6%
Equity (SPY)	11.1%	17.0%	0.50	41.0%
Gold (GLD)	22.1%	17.8%	1.02	5.1%
Commodities (DBC)	11.8%	18.8%	0.52	8.4%
Real Estate (VNQ)	3.7%	18.8%	0.10	30.8%
Bitcoin (BTCUSD)	4.0%	56.5%	0.29	18.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with DXCM
DXCM	14.3%	48.3%	0.47	-
Sector ETF (XLV)	9.8%	16.5%	0.48	36.0%
Equity (SPY)	13.8%	17.9%	0.66	38.1%
Gold (GLD)	14.2%	15.9%	0.74	4.5%
Commodities (DBC)	8.6%	17.6%	0.41	11.5%
Real Estate (VNQ)	5.1%	20.7%	0.22	27.8%
Bitcoin (BTCUSD)	67.4%	66.9%	1.07	10.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	3312026
Short Interest: Shares Quantity	14.7 Mil
Short Interest: % Change Since 3152026	-9.7%
Average Daily Volume	4.2 Mil
Days-to-Cover Short Interest	3.5 days
Basic Shares Quantity	386.6 Mil
Short % of Basic Shares	3.8%

Returns Analyses

	Title
0	Would You Still Hold DexCom Stock If It Fell 30%?
1	DXCM YTD Stock Return Of -7.7% Outperforms IDXX by 2.7% and Underperforms PODD by -3.6%
2	DexCom Stock Return Comparison
3	[10/7/2021] DexCom (DXCM) Stock Price Forecast: AI Forecasts DXCM Stock Price To Be Around $564 In A Month (Up 4.7%)

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
1/12/2026	5.3%	3.2%	1.1%
10/30/2025	-14.6%	-14.9%	-5.5%
7/30/2025	-9.3%	-14.2%	-15.7%
5/1/2025	16.2%	21.5%	21.7%
1/13/2025	2.7%	8.5%	11.1%
10/24/2024	-1.9%	-5.8%	-2.7%
7/25/2024	-40.7%	-34.8%	-31.3%
4/25/2024	-9.9%	-8.2%	-7.7%
...
SUMMARY STATS
# Positive	10	10	10
# Negative	13	13	13
Median Positive	9.7%	10.8%	11.1%
Median Negative	-5.6%	-8.2%	-9.7%
Max Positive	19.4%	21.5%	40.6%
Max Negative	-40.7%	-34.8%	-31.3%

	Forward Returns
1/12/2026	5.3%	3.2%	1.1%
10/30/2025	-14.6%	-14.9%	-5.5%
7/30/2025	-9.3%	-14.2%	-15.7%
5/1/2025	16.2%	21.5%	21.7%
1/13/2025	2.7%	8.5%	11.1%
10/24/2024	-1.9%	-5.8%	-2.7%
7/25/2024	-40.7%	-34.8%	-31.3%
4/25/2024	-9.9%	-8.2%	-7.7%
1/8/2024	4.6%	0.8%	0.8%
10/26/2023	10.1%	15.5%	40.6%
7/27/2023	2.3%	-5.6%	-22.1%
4/27/2023	-1.8%	-5.0%	-6.9%
1/9/2023	-5.0%	-6.3%	-5.5%
10/27/2022	19.4%	11.2%	11.2%
7/28/2022	-5.6%	2.9%	-2.9%
4/28/2022	-1.1%	-8.2%	-30.0%
1/10/2022	-1.9%	-5.1%	-9.7%
10/28/2021	9.3%	10.4%	0.1%
7/29/2021	13.0%	14.9%	14.2%
4/29/2021	-8.4%	-15.3%	-12.4%
1/11/2021	-4.5%	-8.7%	3.3%
10/26/2020	-8.9%	-25.4%	-25.0%
4/28/2020	10.2%	16.2%	15.4%
SUMMARY STATS
# Positive	10	10	10
# Negative	13	13	13
Median Positive	9.7%	10.8%	11.1%
Median Negative	-5.6%	-8.2%	-9.7%
Max Positive	19.4%	21.5%	40.6%
Max Negative	-40.7%	-34.8%	-31.3%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
12/31/2025	02/12/2026	10-K
09/30/2025	10/30/2025	10-Q
06/30/2025	07/30/2025	10-Q
03/31/2025	05/01/2025	10-Q
12/31/2024	02/18/2025	10-K
09/30/2024	10/24/2024	10-Q
06/30/2024	07/25/2024	10-Q
03/31/2024	04/25/2024	10-Q
12/31/2023	02/08/2024	10-K
09/30/2023	10/26/2023	10-Q
06/30/2023	07/27/2023	10-Q
03/31/2023	04/27/2023	10-Q
12/31/2022	02/09/2023	10-K
09/30/2022	10/27/2022	10-Q
06/30/2022	07/28/2022	10-Q
03/31/2022	04/28/2022	10-Q

Recent Forward Guidance [BETA]

Latest: Q4 2025 Earnings Reported 2/12/2026

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
2026 Revenue	5.16 Bil	5.21 Bil	5.25 Bil	12.2%		Higher New	Guidance: 4.64 Bil for 2025
2026 Revenue Growth	11.0%	12.0%	13.0%	-20.0%	-3.0%	Lower New	Guidance: 15.0% for 2025
2026 Non-GAAP Gross Profit Margin	63.0%	63.5%	64.0%	4.1%	2.5%	Higher New	Guidance: 61.0% for 2025
2026 Non-GAAP Operating Margin	22.0%	22.5%	23.0%	9.8%	2.0%	Higher New	Guidance: 20.5% for 2025
2026 Adjusted EBITDA Margin	30.0%	30.5%	31.0%	3.4%	1.0%	Higher New	Guidance: 29.5% for 2025

Prior: Q3 2025 Earnings Reported 10/30/2025

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
2025 Revenue	4.63 Bil	4.64 Bil	4.65 Bil	0.6%		Raised	Guidance: 4.61 Bil for 2025
2025 Revenue Growth		15.0%		3.4%	0.5%	Raised	Guidance: 14.5% for 2025
2025 Non-GAAP Gross Profit Margin		61.0%		-1.6%	-1.0%	Lowered	Guidance: 62.0% for 2025
2025 Non-GAAP Operating Margin	20.0%	20.5%	21.0%	-2.4%	-0.5%	Lowered	Guidance: 21.0% for 2025
2025 Adjusted EBITDA Margin	29.0%	29.5%	30.0%	-1.7%	-0.5%	Lowered	Guidance: 30.0% for 2025

Insider Activity

Expand for More

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Collins, Richard Alexander		by Trust	Sell	11182025	59.05	2,906	171,599	2,071,946	Form
2	Heller, Bridgette P		Direct	Sell	11122025	58.07	1,012	58,767	1,569,690	Form
3	Leach, Jacob Steven	President & COO	Direct	Buy	11102025	55.04	18,200	1,001,702	18,256,127	Form
4	Collins, Richard Alexander		by Trust	Sell	11102025	55.17	3,948	217,811	2,096,129	Form
5	Malady, Kyle		Direct	Sell	9092025	80.86	667	53,934	1,832,854	Form

Collapse to Preview

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Collins, Richard Alexander		by Trust	Sell	11182025	59.05	2,906	171,599	2,071,946	Form
2	Heller, Bridgette P		Direct	Sell	11122025	58.07	1,012	58,767	1,569,690	Form
3	Leach, Jacob Steven	President & COO	Direct	Buy	11102025	55.04	18,200	1,001,702	18,256,127	Form
4	Collins, Richard Alexander		by Trust	Sell	11102025	55.17	3,948	217,811	2,096,129	Form
5	Malady, Kyle		Direct	Sell	9092025	80.86	667	53,934	1,832,854	Form
6	Stern, Sadie	EVP, Chief HR Officer	Direct	Sell	9082025	80.00	1,466	117,280	8,417,840	Form
7	Sylvain, Jereme M	EVP, Chief Financal Officer	Direct	Sell	9042025	74.17	4,824	357,796	8,800,790	Form
8	Brown, Michael Jon	EVP, Chief Legal Officer	Direct	Sell	8182025	80.29	500	40,145	7,555,450	Form
9	Foletta, Mark G		by Trust	Sell	8182025	81.06	2,750	222,903	4,143,642	Form
10	Stern, Sadie	EVP, Chief HR Officer	Direct	Sell	7292025	88.99	1,466	130,459	9,494,254	Form
11	Foletta, Mark G		by Trust	Sell	7172025	85.17	2,750	234,217	4,588,177	Form
12	Brown, Michael Jon	EVP, Chief Legal Officer	Direct	Sell	7172025	86.03	500	43,015	8,138,610	Form
13	Stern, Sadie	EVP, Chief HR Officer	Direct	Sell	6302025	85.06	1,466	124,698	9,199,664	Form
14	Foletta, Mark G		by Trust	Sell	6182025	83.13	2,750	228,605	4,706,847	Form
15	Brown, Michael Jon	EVP, Chief Legal Officer	Direct	Sell	6182025	82.80	500	41,400	7,874,446	Form
16	Augustinos, Nicholas		by Trust	Sell	6172025	81.69	2,618	213,864	3,029,310	Form
17	Augustinos, Nicholas		by Trust	Sell	6172025	82.80	3,672	304,042	2,766,431	Form
18	Stern, Sadie	EVP, Chief HR Officer	Direct	Sell	5282025	85.11	6,184	526,318	9,329,810	Form
19	Brown, Michael Jon	EVP, Chief Legal Officer	Direct	Sell	5282025	84.28	10,000	842,849	8,057,805	Form
20	Heller, Bridgette P		Direct	Sell	3192025	70.33	352	24,756	1,617,379	Form
21	Leach, Jacob Steven	EVP, Chief Operating Officer	Direct	Sell	3142025	70.38	14,076	990,670	22,063,950	Form
22	Brown, Michael Jon	EVP, Chief Legal Officer	Direct	Sell	3142025	70.38	13,000	914,941	7,432,279	Form
23	Sylvain, Jereme M	EVP, Chief Financal Officer	Direct	Sell	3142025	70.38	12,001	844,632	8,690,605	Form
24	Stern, Sadie	EVP, Chief HR Officer	Direct	Sell	3142025	70.38	11,176	786,568	8,150,367	Form
25	Sayer, Kevin R	Chairman, CEO & President	Direct	Sell	3142025	70.38	32,498	2,287,212	26,183,438	Form
26	Sylvain, Jereme M	EVP, Chief Financal Officer	Direct	Sell	3112025	73.83	7,000	516,830	10,003,029	Form
27	Heller, Bridgette P		Direct	Sell	2172026	68.01	1,012	68,826	1,769,552	Form
28	Brown, Michael Jon	EVP, Chief Legal Officer	Direct	Sell	3182026	64.85	1,700	110,245	7,321,824	Form

DXCM Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing DXCM?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What DXCM Makes & Who Pays

TTM figures based on

DXCM Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Health Care Equipment Resources

MedTech Dive

MassDevice

Fierce Medical Devices

Medical Device and Diagnostic Industry

MD+DI

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

DexCom (DXCM)

Market Price (4/11/2026): $64.0 | Market Cap: $24.7 BilSector: Health Care | Industry: Health Care Equipment

DexCom (DXCM)

Market Price (4/11/2026): $64.0Market Cap: $24.7 BilSector: Health CareIndustry: Health Care Equipment

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About DexCom (DXCM)

Addressable Markets for DexCom's Main Products and Services

Global Continuous Glucose Monitoring (CGM) Market

U.S. Continuous Glucose Monitoring (CGM) Market

Dexcom Stelo Addressable Market (U.S.)

Expected Drivers of Future Revenue Growth for DexCom (DXCM)

Capital Allocation Decisions (2021-2025)

Share Repurchases

Capital Expenditures

Interactive Breakdown

Better Bets vs. DexCom (DXCM)

INDUSTRY: Health Care Equipment

Higher Rev Chg 3Y Avg | Lower P/S (Values for DXCM: 17.1% | 5.3x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for DXCM: 17.1% | 27.1x)

Higher Rev Chg LTM (Value for DXCM: 15.6%)

Higher Rev Chg 3Y Avg (Value for DXCM: 17.1%)

Higher Op Mgn LTM (Value for DXCM: 19.6%)

Higher CFO/Rev LTM (Value for DXCM: 30.9%)

Higher FCF/Rev LTM (Value for DXCM: 23.1%)

Higher Total Yield (Value for DXCM: 3.4%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for DXCM: 17.1% | 5.3x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for DXCM: 17.1% | 27.1x)

Higher Rev Chg LTM (Value for DXCM: 15.6%)

Higher Rev Chg 3Y Avg (Value for DXCM: 17.1%)

Higher Op Mgn LTM (Value for DXCM: 19.6%)

Higher CFO/Rev LTM (Value for DXCM: 30.9%)

Higher FCF/Rev LTM (Value for DXCM: 23.1%)

Higher Total Yield (Value for DXCM: 3.4%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for DXCM: 17.1% | 5.3x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for DXCM: 17.1% | 27.1x)

Higher Rev Chg LTM (Value for DXCM: 15.6%)

Higher Rev Chg 3Y Avg (Value for DXCM: 17.1%)

Higher Op Mgn LTM (Value for DXCM: 19.6%)

Higher CFO/Rev LTM (Value for DXCM: 30.9%)

Higher FCF/Rev LTM (Value for DXCM: 23.1%)

Higher Total Yield (Value for DXCM: 3.4%)

Best Bets in Health Care

P/EBIT (Value for DXCM: 22.4x)

P/E (Value for DXCM: 29.6x)

Rev Chg 3Y Avg (Value for DXCM: 17.1%)

Rev Chg LTM (Value for DXCM: 15.6%)

Rev Chg Q (Value for DXCM: 13.1%)

FCF/Rev 3Y Avg (Value for DXCM: 17.6%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Market Price (4/11/2026): $64.0 | Market Cap: $24.7 Bil
Sector: Health Care | Industry: Health Care Equipment

Market Price (4/11/2026): $64.0
Market Cap: $24.7 Bil
Sector: Health Care
Industry: Health Care Equipment